5-Amino-1MQ – 50mg

5-Amino-1MQ – 50mg

NNMT Inhibitor for Metabolic, Cellular Energy & Body-Composition Research

What Is 5-Amino-1MQ?

5-Amino-1MQ, or 5-amino-1-methylquinolinium, is an experimental small molecule developed to selectively inhibit the enzyme nicotinamide N-methyltransferase (NNMT).

Although frequently grouped with peptides in metabolic and longevity research, 5-Amino-1MQ is not technically a peptide. Its interest comes from research connecting NNMT activity with adipose-tissue metabolism, cellular energy regulation, NAD⁺ biology, and metabolic dysfunction.

NNMT uses nicotinamide and the methyl donor S-adenosylmethionine (SAM) to produce 1-methylnicotinamide (1-MNA). NNMT expression is elevated in white adipose tissue in several experimental models of obesity and metabolic dysfunction, making the enzyme an intriguing metabolic target.

5-Amino-1MQ was developed as a selective, cell-permeable NNMT inhibitor to investigate what happens when this pathway is suppressed.

What Does It Do?

Preclinical research suggests that inhibition of NNMT by 5-Amino-1MQ may:

Reduce fat accumulation and adipocyte size

Suppress lipogenesis within fat cells

Increase cellular energy expenditure

Influence NAD⁺-related metabolism

Preserve cellular methyl-donor availability

Support healthier glucose metabolism

Improve metabolic flexibility

Influence skeletal-muscle regeneration and function

An especially interesting feature of the original obesity research was that reductions in body weight and adipose tissue occurred in mice without a significant reduction in food intake, suggesting that the observed effect was related to altered cellular metabolism rather than simple appetite suppression.

How Does It Function in the Body?

1. Inhibits NNMT

5-Amino-1MQ selectively inhibits nicotinamide N-methyltransferase (NNMT).

NNMT normally converts:

Nicotinamide + SAM → 1-Methylnicotinamide + SAH

Blocking this pathway changes how cells utilize nicotinamide and methyl donors, potentially influencing several pathways involved in cellular energy metabolism.

2. Influences NAD⁺ Metabolism

Nicotinamide is an important component of the cellular NAD⁺ salvage pathway.

By reducing NNMT-mediated nicotinamide methylation, experimental research suggests 5-Amino-1MQ can increase intracellular NAD⁺ availability in adipocytes.

NAD⁺ is essential for:

Mitochondrial energy metabolism

Cellular redox reactions

ATP production

Sirtuin activity

DNA-repair pathways

Metabolic signaling

This creates an interesting mechanistic connection between NNMT inhibition and cellular energy regulation.

3. Influences the Cellular Methylation Environment

NNMT also consumes SAM (S-adenosylmethionine), one of the body’s primary methyl donors.

High NNMT activity can therefore influence both nicotinamide metabolism and cellular methylation chemistry.

Inhibiting NNMT may help preserve SAM availability and alter metabolic signaling within adipose tissue.

4. Alters Adipocyte Energy Metabolism

This is where 5-Amino-1MQ becomes particularly interesting for metabolic research.

Experimental studies found that NNMT inhibition altered the metabolic behavior of adipocytes and reduced lipogenesis.

In diet-induced obese mice, researchers observed reductions in:

Body weight

White adipose tissue mass

Adipocyte size

These effects occurred without a corresponding reduction in food consumption.

Rather than primarily acting as an appetite suppressant, 5-Amino-1MQ is therefore being investigated as a cellular metabolic modulator.

What Do Studies Show?

The research surrounding NNMT inhibition is promising, but an important distinction needs to be made:

Current evidence for 5-Amino-1MQ is predominantly preclinical. Human efficacy and long-term safety have not been established.

Laboratory and animal studies have reported that 5-Amino-1MQ:

Selectively inhibits NNMT

Reduces intracellular 1-MNA

Increases intracellular NAD⁺ in adipocytes

Suppresses lipogenesis

Reduces body weight in diet-induced obese mice

Reduces white adipose tissue mass

Decreases adipocyte size

Produces metabolic changes without significantly reducing food intake

Additional mouse research combining NNMT inhibition with a reduced-calorie diet found improvements in body composition and several obesity-associated metabolic abnormalities.

NNMT itself is also being investigated in relation to type 2 diabetes, fatty liver disease, skeletal-muscle aging, and other metabolic conditions.

However, these findings should not be interpreted as demonstrated human benefits. There is currently no established human clinical dose, efficacy profile, or long-term safety profile for 5-Amino-1MQ.

Overall Research Interests

Based on current preclinical evidence, 5-Amino-1MQ is primarily being investigated for its potential role in:

✓ Body Composition
Research into adipose-tissue accumulation and fat-cell metabolism

✓ Metabolic Optimization
Investigation of cellular pathways involved in energy expenditure and metabolic flexibility

✓ NAD⁺ Metabolism
Potential preservation of nicotinamide for NAD⁺-related cellular pathways

✓ Cellular Energy
Research into metabolic signaling and cellular energy expenditure

✓ Glucose Metabolism
Investigation of NNMT as a target in obesity-associated metabolic dysfunction

✓ Healthy Aging Research
Emerging research into NNMT activity, muscle function, and age-associated metabolic changes

Scientific Positioning

5-Amino-1MQ represents a fundamentally different approach to metabolic research. Rather than acting primarily through appetite-regulating receptors, it targets NNMT—an intracellular metabolic enzyme involved in nicotinamide, NAD⁺ and methyl-donor metabolism.

By selectively inhibiting NNMT, 5-Amino-1MQ is being investigated for its ability to alter adipocyte metabolism, cellular energy expenditure and body composition.

The concept is compelling, but the distinction between preclinical potential and demonstrated human efficacy is important. At present, the strongest evidence comes from cellular and animal models.

Research Use Only

5-Amino-1MQ is an investigational research compound and is not FDA-approved for the treatment, prevention, or diagnosis of obesity, diabetes, metabolic disease, or any other medical condition.